New drug combo targets rare bladder cancer
NCT ID NCT06228066
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This phase II trial tests two drugs, lurbinectedin and avelumab, in people with a rare and aggressive bladder cancer called small cell carcinoma. Participants who have already had a drug like avelumab will receive only lurbinectedin; others will get both. The study aims to see if these drugs can shrink tumors and control the disease for longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lurbinectedin and avelumab
- What this could lead to
- If successful, this could provide a new treatment option for a rare and aggressive bladder cancer that has spread after initial therapy.
- What could go wrong
- This is a small, early-phase trial with only 45 participants, so results may not apply to everyone. The drugs can cause side effects, and it's unknown if they will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE TUMORS OF THE URINARY TRACT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.